Abstract
This study aims to investigate the efficacy of bevacizumab-combined chemotherapy (BCC) in Chinese stage IV colorectal cancer (CRC), and analyze the relationship between clinicopathological features with survival. Patients with stage IV CRC treated with BCC were analyzed retrospectively. 217 metastatic CRC (mCRC) patients were collected, out of which79 were right-sided CRCs and 138 were left-sided ones. Patients with Eastern Cooperative Oncology Group (ECOG) performance status ≤2, single agent chemotherapy, poor/mucous/signet ring cell component, second-and further-line of bevacizumab administration, multiple metastasis sites had comparatively worse survival. Among 141 patients with known KRAS status, 55 patients harbored KRAS mutation and 86 had wild type KRAS. The ORR and DCR were 41.9% and 78.9%, respectively, in patients with wild type KRAS, while ORR and DCR was 38.7% and 77.9%, respectively, in patients with KRAS mutation. The median PFS of patients with wild type and mutant KRAS were 8.38, and9.59 months, respectively; whereas the OS was 23.00 and 21.26 months, respectively for mCRC patients with wild-type and mutant KRAS. Cumulatively, our study indicated that BCC was effective and beneficial for Chinese stage IV CRC patients. KRAS mutation status and tumor location were not a prognostic factor for survival.
Highlights
Colorectal cancer (CRC) is one of the most common malignancies globally and is the third major cause of cancer morbidity and mortality[1]
Baseline demographics and clinical characteristics are summarized in Table 1. 169 patients had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) scored 0–1 and 48 patients scored 2 at the initial bevacizumab administration
The overall response rate (ORR) and disease-control rate (DCR) were 51.5% and 96.2% when bevacizumab was administered in first-line therapy and 25.5% and 78.2% when administered in second-line therapy
Summary
Colorectal cancer (CRC) is one of the most common malignancies globally and is the third major cause of cancer morbidity and mortality[1]. While the benefits of treatment with bevacizumab are well studied in American and European patients with stage IV CRC, the effect and safety of treatment with bevacizumab combined chemotherapy in Chinese patients, and whether the KRAS mutation status and primary tumor site could affect the prognosis of Chinese stage IV CRC have not been demonstrated clearly. This retrospective study aimed at investigating the efficacy and safety profile of combination treatment with bevacizumab in Chinese stage IV CRC patients and analyzing prognostic factors for predicting patients’ survival
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
